LDLR and metabolic dysfunction-associated steatohepatitis: Therefore, we evaluated the effects of semaglutide on pathophysiological pathways specific for severe fibrosis by comparing the hepatic transcriptomic signature of Ldlr-/-.Leiden mice with a human gene profile published by Moylan et al. that differentiates NASH patients with severe fibrosis (stage F3 or F4) from NASH patients with mild fibrosis (stage F0 or F1) (Figure 6B) [22].